William L Hwang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9343064/publications.pdf Version: 2024-02-01



WILLIAM L HWANC

#	Article	IF	CITATIONS
1	Droplet interface bilayers. Molecular BioSystems, 2008, 4, 1191.	2.9	411
2	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	329.8	237
3	Droplet networks with incorporated protein diodes show collective properties. Nature Nanotechnology, 2009, 4, 437-440.	31.5	210
4	Safety of combining radiotherapy with immune-checkpoint inhibition. Nature Reviews Clinical Oncology, 2018, 15, 477-494.	27.6	208
5	Asymmetric Droplet Interface Bilayers. Journal of the American Chemical Society, 2008, 130, 5878-5879.	13.7	195
6	ISWI Remodelers Slide Nucleosomes with Coordinated Multi-Base-Pair Entry Steps and Single-Base-Pair Exit Steps. Cell, 2013, 152, 442-452.	28.9	150
7	Screening Blockers Against a Potassium Channel with a Droplet Interface Bilayer Array. Journal of the American Chemical Society, 2008, 130, 15543-15548.	13.7	139
8	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	16.8	119
9	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	14.3	111
10	Electrical Behavior of Droplet Interface Bilayer Networks:  Experimental Analysis and Modeling. Journal of the American Chemical Society, 2007, 129, 11854-11864.	13.7	98
11	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro-Oncology, 2016, 18, 863-872.	1.2	91
12	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	28.9	84
13	Histone H4 tail mediates allosteric regulation of nucleosome remodelling by linker DNA. Nature, 2014, 512, 213-217.	27.8	78
14	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. JAMA Oncology, 2018, 4, 253.	7.1	76
15	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	7.1	65
16	Epi-illumination through the microscope objective applied to darkfield imaging and microspectroscopy of nanoparticle interaction with cells in culture. Optics Express, 2006, 14, 6535.	3.4	40
17	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. Journal of Neurosurgery, 2018, 128, 1123-1132.	1.6	37
18	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncology, The, 2022, 23, e62-e74.	10.7	36

WILLIAM L HWANG

#	Article	IF	CITATIONS
19	Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiotherapy and Oncology, 2020, 142, 154-161.	0.6	30
20	The role of radiotherapy in the management of high-grade meningiomas. Chinese Clinical Oncology, 2017, 6, S5-S5.	1.2	25
21	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews, 2018, 125, 122-131.	13.7	21
22	Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer, 2019, 125, 1357-1364.	4.1	18
23	Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 177-184.	4.9	16
24	Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study. Oral Oncology, 2019, 98, 28-34.	1.5	12
25	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. Clinical Cancer Research, 2021, 27, 2807-2815.	7.0	12
26	The promise of circulating tumor cells for precision cancer therapy. Biomarkers in Medicine, 2016, 10, 1269-1285.	1.4	11
27	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clinical Cancer Research, 2021, 27, 3825-3833.	7.0	8
28	Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 1207-1209.	4.4	5
29	Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. Journal of Neuro-Oncology, 2020, 148, 81-88.	2.9	5
30	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. Oral Oncology, 2018, 86, 69-74.	1.5	4
31	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.4	2
32	Immune-related adverse events (IRAEs) in metastatic lung cancer patients receiving PD-1/PD-L1 inhibitors and thoracic radiotherapy Journal of Clinical Oncology, 2017, 35, 9079-9079.	1.6	2
33	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy—Reply. JAMA Oncology, 2018, 4, 1620.	7.1	0
34	Silver Linings: An Opportunity to Improve Clinical Paradigms After the COVID-19 Pandemic. JCO Oncology Practice, 2020, 16, 532-534.	2.9	0
35	Severe lymphopenia predicts poorer survival in patients with rectal cancer undergoing neoadjuvant chemoradiation Journal of Clinical Oncology, 2021, 39, 138-138.	1.6	0
36	Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer. Journal of Clinical Oncology, 2021, 39, 439-439.	1.6	0

#	Article	IF	CITATIONS
37	Abstract 94: Multi-compartment reprogramming and spatially-resolved interactions in frozen pancreatic cancer with and without neoadjuvant chemotherapy and radiotherapy at single-cell resolution. , 2021, , .		0
38	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis Journal of Clinical Oncology, 2018, 36, 24-24.	1.6	0
39	Abstract PR-006: Integrative genomic characterization of therapeutic targets for pancreatic cancer. , 2021, , .		0
40	Spatially defined enrichment of a neuronal-like malignant phenotype in pancreatic cancer after neoadjuvant treatment Journal of Clinical Oncology, 2022, 40, 610-610.	1.6	0
41	DNA repair and immune checkpoint blockade response. Cancer Genetics, 2022, 264-265, 1-4.	0.4	0
42	Abstract SY12-04: Multicellular spatial community featuring a novel neuronal-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy. Cancer Research, 2022, 82, SY12-04-SY12-04.	0.9	0